Skip to content
Markets

Roche's Sales Growth Speeds Up to 7% in the Third Quarter as It Confirms Its 2026 Outlook

Roche's third-quarter sales rose 7% at constant currencies and 8% in Swiss francs, taking nine-month sales to CHF 46.5bn. The group confirmed its 2026 targets as Xolair, Hemlibra and Phesgo grew.

Roche's two headquarters towers, Building 1 and Building 2, rise above the Rhine in Basel, Switzerland.
Photo: Tilman2007 / Wikimedia Commons, CC BY-SA 4.0

Roche's sales growth picked up in the third quarter to 7% at constant exchange rates and 8% in Swiss francs, the group said on 22 October. Nine-month sales reached CHF 46.5 billion, and Roche confirmed its 2026 targets for sales, core earnings per share and a higher dividend.

Growth speeds up as the franc stops biting

Group sales for the first nine months of 2026 were CHF 46,493 million, against CHF 45,862 million a year earlier. That is growth of 6% at constant exchange rates (CER) but only 1% in Swiss francs, because the stronger franc, especially against the US dollar, cut the reported figure for much of the year.

That currency drag reversed in the third quarter as exchange rates stabilised, so quarterly growth of 7% at CER turned into 8% in francs. Chief executive Thomas Schinecker said the group "continued to make meaningful progress for patients."

Roche: share price, chart and news

Roche, first nine months of 2026

  • CHF 46.5bn group sales, up 6% at CER and 1% in francs
  • CHF 36.2bn pharmaceuticals sales, up 7% at CER
  • CHF 10.3bn diagnostics sales, up 4% at CER
Roche buildings on the Rhine bank along Grenzacher Strasse in Basel, one carrying the Roche logo, with the lower floors of a Roche tower rising behind them on the left.
Roche buildings on the Rhine bank along Grenzacher Strasse in Basel, one carrying the Roche logo, with the lower floors of a Roche tower rising behind them on the left. Photo: Tilman2007 / Wikimedia Commons, CC BY-SA 4.0

Medicines: five products carry the growth

The pharmaceuticals division, which supplied 77.9% of group sales, grew 7% at CER. Roche's five biggest growth drivers, Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo, together sold CHF 16.8 billion, up 12% at CER.

ProductNine-month salesGrowth at CER
Ocrevus (multiple sclerosis)CHF 5,317m+7%
Hemlibra (haemophilia A)CHF 3,750m+12%
Vabysmo (eye disease)CHF 3,196m+10%
Xolair (allergy, asthma)CHF 2,521m+20%
Phesgo (breast cancer)CHF 2,064m+18%
Polivy (lymphoma)CHF 1,302m+24%

By region, pharmaceuticals sales rose 5% at CER in the United States, Roche's largest market, at CHF 18.7 billion, and 2% in Europe. Japan grew 25% at CER, which Roche put down partly to product supply to third parties and a positive timing effect from the introduction of a new ERP system, alongside growth in several medicines. China was flat.

Older medicines kept shrinking. Products that have lost patent protection, Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra/RoActemra, fell by a combined CHF 0.4 billion at CER. Actemra/RoActemra sales fell 10% overall and 26% in Europe, where it faces biosimilars, and Perjeta fell 8% as patients moved to Phesgo.

Diagnostics: China pricing weighs on Asia-Pacific

The diagnostics division grew 4% at CER to CHF 10.3 billion, flat in francs. Core lab sales rose 5%, pathology lab sales 10% and molecular lab sales 3%, and Roche said demand for core lab and pathology products more than offset healthcare pricing reforms in China. Near patient care sales fell 5% at CER to CHF 1.35 billion; the release gave no reason. Asia-Pacific diagnostics sales fell 4% at CER, while North America grew 9%.

Pipeline news and what to watch

Roche listed several regulatory steps in the quarter. The US Food and Drug Administration approved Tecentriq after surgery for a form of stage III colon cancer on 9 October and Enspryng for thyroid eye disease on 16 October, and granted priority review to fenebrutinib in relapsing and primary progressive multiple sclerosis on 30 September.

Dates ahead

  • 30 November 2026: FDA decision date for giredestrant in early-stage breast cancer
  • 18 December 2026: FDA decision date for giredestrant in advanced breast cancer
  • 9 March 2027: Roche annual general meeting
  • By July 2027: expected FDA decision on vamikibart in uveitic macular edema

For 2026, Roche still expects group sales growth in the mid single digits at CER, core earnings per share growth in the high single digits at CER, and a further increase in the dividend in Swiss francs.

The main risks are the ones visible in these numbers. Biosimilars continue to erode older brands, China's pricing reforms weigh on diagnostics, and the strong franc can shrink reported growth even when underlying demand holds. The giredestrant decisions are binary events: a delay or rejection would remove an expected launch from Roche's plans for late 2026.

Sources

Related stories

Markets

Roche Shares Climb as Divarasib Cuts the Risk of Death by 44% in Lung Cancer

Roche shares opened about 1.5% higher on Monday after divarasib cut the risk of death by 44% against approved KRAS G12C drugs in a Phase III lung cancer trial, extending an 11.7%…

Business

Roche Wins FDA Approval for Breast Cancer Pill Wilserdly After 62% Cut in Progression Risk

The FDA approved Roche's all-pill Wilserdly combination for ESR1-mutated advanced breast cancer after it cut the risk of progression or death by 62%. A ruling on early-stage use is…

Markets

Nestlé's Volume Growth Speeds Up to 2.8% as Navratil's Turnaround Gains Pace

Nestlé's third-quarter organic growth reached 4.0%, beating the 3.5% analysts expected, as volume growth rose to 2.8% from 1.8%. Guidance is unchanged, and Russia has been taken…

Markets

Alkane Resources Starts FY27 With 40,740 Ounces and A$440m in Cash and Bullion

Alkane Resources produced 40,740 gold-equivalent ounces in the September quarter at an AISC of A$2,805, paid its first dividend and held A$440m in cash and bullion. Full-year…

Markets

Bitcoin Falls to $62,000 as $2bn of Leveraged Bets Are Wiped Out in Sixth Weekly Loss

Bitcoin fell to about $62,000 at the weekend as $2bn of leveraged bets were liquidated, its sixth straight weekly loss. It was back near $65,000 on Monday, with $60,000 the next…

Markets

Copper Hits a Four-Month Low at $13,210 as AI Doubts Drag European Miners Down 2.3%

Copper fell to $13,210 a tonne on Monday, a four-month low about 10% below September's record, as AI doubts and weak Chinese data hit metals and Europe's basic resources shares…

Markets

Bessent Urges an Outside CEO for Nvidia as Shares Fall 4.1% Before Results

Treasury Secretary Scott Bessent wants Nvidia to hire an outside chief executive, the board is not discussing Jensen Huang's return, and the shares fell 4.1% on Monday, a day…

Markets

Chip Index Sinks 5.28% With All 30 Stocks Down, Dragging the Nasdaq 2.49% Before Nvidia

The Philadelphia Semiconductor Index fell 5.28% on Monday 16 November with all 30 members down, pulling the Nasdaq 2.49% lower and the Dow down 739 points before Nvidia reports.